Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Sanofi (SNYNF) Common Equity (2016 - 2025)

Historic Common Equity for Sanofi (SNYNF) over the last 17 years, with Q4 2025 value amounting to $83.1 billion.

  • Sanofi's Common Equity rose 32.44% to $83.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $83.1 billion, marking a year-over-year increase of 32.44%. This contributed to the annual value of $80.7 billion for FY2025, which is 384.63% down from last year.
  • As of Q4 2025, Sanofi's Common Equity stood at $83.1 billion, which was up 32.44% from $79.2 billion recorded in Q2 2025.
  • In the past 5 years, Sanofi's Common Equity ranged from a high of $83.1 billion in Q4 2025 and a low of $75.7 billion during Q2 2022
  • Moreover, its 5-year median value for Common Equity was $78.8 billion (2021), whereas its average is $78.9 billion.
  • Per our database at Business Quant, Sanofi's Common Equity soared by 921.84% in 2021 and then crashed by 289.03% in 2022.
  • Sanofi's Common Equity (Quarter) stood at $78.6 billion in 2021, then fell by 2.89% to $76.3 billion in 2022, then grew by 4.41% to $79.7 billion in 2023, then increased by 3.97% to $82.8 billion in 2024, then increased by 0.32% to $83.1 billion in 2025.
  • Its Common Equity stands at $83.1 billion for Q4 2025, versus $79.2 billion for Q2 2025 and $82.8 billion for Q4 2024.